恒瑞医药两款药品临床试验获批

Core Viewpoint - Heng Rui Medicine announced that its subsidiaries have received approval from the National Medical Products Administration for clinical trials of SHR-7787 injection and Adebeli monoclonal antibody injection, which will commence shortly [1] Group 1: Product Details - SHR-7787 injection is a Class 1 therapeutic biological product that activates T cells to target and kill tumor cells [1] - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody developed by the company, which blocks the PD-1/PD-L1 pathway to reactivate the immune system's anti-tumor activity [1]